AGN 211.62 Allergan Inc $AGN Hit a 52 week high of
Post# of 58
Posted On: 11/18/2014 10:14:07 AM
AGN 211.62 Allergan Inc $AGN Hit a 52 week high of 211.97 Closing the day 09:45 at 211.62 +2.42 +1.16% With a day low of 207.18 and a total volume of 961,195.
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics
PR Newswire - 43 mins ago
Today, Zacks Investment Ideas feature highlights Features: Allergan (NYSE:AGN-Free Report), Actavis (NYSE:ACT-Free Report), Sketchers (NYSE:SKX-Free Report) and Zeltiq Aesthetics (Nasdaq:ZLTQ-Free Report).
AGN: 213.34 (+4.14)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 1 hr 41 mins ago
AGN: 213.34 (+4.14), VRX: 141.60 (+4.87), ACT: 263.34 (+15.40)
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - 2 hrs 17 mins ago
Allergan (AMEX:AGN) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $209.20 on volume of 19.1 million shares, above average daily volume of 2.7 million. In the past 52 weeks, Allergan share prices have been bracketed by a low of $94.98 and a high of $213.91 and closed yesterday at $209.20, 120% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.2%.
AGN: 213.34 (+4.14)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.75 (+0.84), BIIB: 305.50 (+3.08), GE: 26.81 (+0.20), NKE: 96.28 (+0.22), HAL: 49.90 (+0.67), TSN: 42.91 (-0.12), GSAT: 2.61 (-0.19), LULU: 45.39 (+0.97), AGN: 213.34 (+4.14), MACK: 8.97 (+0.35), WHR: 176.88 (+1.33), UA: 69.48 (+0.59), DSX: 7.89 (+0.07), ALNY: 91.63 (+2.65), MPC: 92.41 (-0.10), JCP: 7.28 (+0.02), SHW: 240.50 (+1.19), MBLY: 47.29 (+0.31), REGN: 405.46 (+5.81), BHI: 66.18 (+0.95)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 213.34 (+4.14), ACT: 263.34 (+15.40), VRX: 141.60 (+4.87), V: 251.42 (+1.62), ALXN: 191.46 (+4.68), CTSH: 53.15 (+0.09), MA: 83.49 (+0.29), ADS: 280.65 (-0.23)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.34 (+4.14), MRK: 59.73 (+0.27), ABBV: 65.79 (+0.75), BMY: 58.84 (+0.41)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 213.34 (+4.14), ACT: 263.34 (+15.40), AMAG: 35.80 (+1.04), BMY: 58.84 (+0.41)
NYSE stocks posting largest volume increases
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
AGN: 213.34 (+4.14), HAL: 49.90 (+0.67), BLT: 16.67 (+0.50), DKL: 40.11 (+0.11), BHI: 66.18 (+0.95)
Watch for Allergan to Potentially Pullback After Gaining 5.21% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 4:28PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.44 to a high of $213.91. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $200.60 on volume of 18.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 213.34 (+4.14)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 213.34 (+4.14), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94), MRK: 59.75 (+0.29), VRX.TO: 160.40 (+6.00)
Halliburton and Allergan are big market movers
AP - Mon Nov 17, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.37 (-0.44), AGN: 213.34 (+4.14), HAS: 56.17 (-0.20), HAL: 49.90 (+0.67), DNR: 9.96 (-0.05), MITL: 10.17 (-0.03), FOLD: 6.36 (-0.34), BHI: 66.18 (+0.95)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 213.34 (+4.14), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), SAFM: 86.51 (+1.58), PPC: 31.26 (+0.32), MIK: 22.14 (+0.49), TSN: 42.91 (-0.12)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.67 (+4.62), HAS: 56.17 (-0.20), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94), JIVE: 6.25 (-0.12), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), DWA: 22.52 (+0.21), AGN: 213.34 (+4.14), LNKD: 222.67 (-0.61), BHI: 66.18 (+0.95), CRM: 63.10 (+0.59)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 213.34 (+4.14), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), LNKD: 222.67 (-0.61), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), BHI: 66.18 (+0.95), Z: 119.93 (+2.07)
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
AGN: 213.34 (+4.14), GE: 26.81 (+0.20), F: 15.57 (+0.03), PFE: 30.44 (+0.12), HAL: 49.90 (+0.67), BAC: 17.11 (+0.02), DNR: 9.96 (-0.05), TWTR: 40.95 (+0.48), BHI: 66.18 (+0.95)
Fitch: Allergan Purchase by Actavis Would Pressure Ratings
Business Wire - Mon Nov 17, 12:44PM CST
Allergan's ratings remain on Rating Watch Negative following Actavis plc's (Actavis) announcement that it plans to acquire Allergan for approximately $66 billion. Allergan presently has $2.1 billion of outstanding debt.
AGN: 213.34 (+4.14)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 213.34 (+4.14), HAS: 56.17 (-0.20), AMZN: 327.67 (+4.62), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), LNKD: 222.67 (-0.61), JIVE: 6.25 (-0.12), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), DWA: 22.52 (+0.21), CRM: 63.13 (+0.62), BHI: 66.18 (+0.95)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 213.34 (+4.14), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94)
Fitch Affirms Actavis at 'BBB-' on Allergan Acquisition Announcement; Outlook Stable
Business Wire - Mon Nov 17, 11:20AM CST
Fitch Ratings has affirmed the ratings of Actavis plc (Actavis; NYSE: ACT) and its subsidiaries at 'BBB-'. The Rating Outlook is Stable.
AGN: 213.34 (+4.14)
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics
PR Newswire - 43 mins ago
Today, Zacks Investment Ideas feature highlights Features: Allergan (NYSE:AGN-Free Report), Actavis (NYSE:ACT-Free Report), Sketchers (NYSE:SKX-Free Report) and Zeltiq Aesthetics (Nasdaq:ZLTQ-Free Report).
AGN: 213.34 (+4.14)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 1 hr 41 mins ago
AGN: 213.34 (+4.14), VRX: 141.60 (+4.87), ACT: 263.34 (+15.40)
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - 2 hrs 17 mins ago
Allergan (AMEX:AGN) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $209.20 on volume of 19.1 million shares, above average daily volume of 2.7 million. In the past 52 weeks, Allergan share prices have been bracketed by a low of $94.98 and a high of $213.91 and closed yesterday at $209.20, 120% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.2%.
AGN: 213.34 (+4.14)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.75 (+0.84), BIIB: 305.50 (+3.08), GE: 26.81 (+0.20), NKE: 96.28 (+0.22), HAL: 49.90 (+0.67), TSN: 42.91 (-0.12), GSAT: 2.61 (-0.19), LULU: 45.39 (+0.97), AGN: 213.34 (+4.14), MACK: 8.97 (+0.35), WHR: 176.88 (+1.33), UA: 69.48 (+0.59), DSX: 7.89 (+0.07), ALNY: 91.63 (+2.65), MPC: 92.41 (-0.10), JCP: 7.28 (+0.02), SHW: 240.50 (+1.19), MBLY: 47.29 (+0.31), REGN: 405.46 (+5.81), BHI: 66.18 (+0.95)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 213.34 (+4.14), ACT: 263.34 (+15.40), VRX: 141.60 (+4.87), V: 251.42 (+1.62), ALXN: 191.46 (+4.68), CTSH: 53.15 (+0.09), MA: 83.49 (+0.29), ADS: 280.65 (-0.23)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.34 (+4.14), MRK: 59.73 (+0.27), ABBV: 65.79 (+0.75), BMY: 58.84 (+0.41)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 213.34 (+4.14), ACT: 263.34 (+15.40), AMAG: 35.80 (+1.04), BMY: 58.84 (+0.41)
NYSE stocks posting largest volume increases
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
AGN: 213.34 (+4.14), HAL: 49.90 (+0.67), BLT: 16.67 (+0.50), DKL: 40.11 (+0.11), BHI: 66.18 (+0.95)
Watch for Allergan to Potentially Pullback After Gaining 5.21% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 4:28PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.44 to a high of $213.91. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $200.60 on volume of 18.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 213.34 (+4.14)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 213.34 (+4.14), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94), MRK: 59.75 (+0.29), VRX.TO: 160.40 (+6.00)
Halliburton and Allergan are big market movers
AP - Mon Nov 17, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.37 (-0.44), AGN: 213.34 (+4.14), HAS: 56.17 (-0.20), HAL: 49.90 (+0.67), DNR: 9.96 (-0.05), MITL: 10.17 (-0.03), FOLD: 6.36 (-0.34), BHI: 66.18 (+0.95)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 213.34 (+4.14), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), SAFM: 86.51 (+1.58), PPC: 31.26 (+0.32), MIK: 22.14 (+0.49), TSN: 42.91 (-0.12)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.67 (+4.62), HAS: 56.17 (-0.20), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94), JIVE: 6.25 (-0.12), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), DWA: 22.52 (+0.21), AGN: 213.34 (+4.14), LNKD: 222.67 (-0.61), BHI: 66.18 (+0.95), CRM: 63.10 (+0.59)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 213.34 (+4.14), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), LNKD: 222.67 (-0.61), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), BHI: 66.18 (+0.95), Z: 119.93 (+2.07)
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
AGN: 213.34 (+4.14), GE: 26.81 (+0.20), F: 15.57 (+0.03), PFE: 30.44 (+0.12), HAL: 49.90 (+0.67), BAC: 17.11 (+0.02), DNR: 9.96 (-0.05), TWTR: 40.95 (+0.48), BHI: 66.18 (+0.95)
Fitch: Allergan Purchase by Actavis Would Pressure Ratings
Business Wire - Mon Nov 17, 12:44PM CST
Allergan's ratings remain on Rating Watch Negative following Actavis plc's (Actavis) announcement that it plans to acquire Allergan for approximately $66 billion. Allergan presently has $2.1 billion of outstanding debt.
AGN: 213.34 (+4.14)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 213.34 (+4.14), HAS: 56.17 (-0.20), AMZN: 327.67 (+4.62), VRX: 141.67 (+4.94), ACT: 263.21 (+15.27), LNKD: 222.67 (-0.61), JIVE: 6.25 (-0.12), FB: 74.49 (+0.25), HAL: 49.90 (+0.67), DWA: 22.52 (+0.21), CRM: 63.13 (+0.62), BHI: 66.18 (+0.95)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 213.34 (+4.14), ACT: 263.21 (+15.27), VRX: 141.67 (+4.94)
Fitch Affirms Actavis at 'BBB-' on Allergan Acquisition Announcement; Outlook Stable
Business Wire - Mon Nov 17, 11:20AM CST
Fitch Ratings has affirmed the ratings of Actavis plc (Actavis; NYSE: ACT) and its subsidiaries at 'BBB-'. The Rating Outlook is Stable.
AGN: 213.34 (+4.14)
(0)
(0)Allergan Inc. (AGN) Stock Research Links
Scroll down for more posts ▼